Skip to main content
. 2021 Mar 16;22(6):3025. doi: 10.3390/ijms22063025

Figure 2.

Figure 2

Overview of therapeutic concepts for patients with KRAS-mutant NSCLC in different stages of clinical development that target mutant KRAS itself or the surrounding tumor immune microenvironment. Future clinical trials are required to decipher the optimal strategy of simultaneously or sequentially combining these treatment strategies. References if applicable are displayed in brackets. Created with biorender.com (accessed on 3 March 2021).